ArticleBMC public health2025
Thirty-year changes in burden for refraction disorders in China, Japan, Korea and Singapore: a jointly prevention perspective analysis.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundUncorrected refractive error is a primary cause of global vision impairment, creating substantial health and economic burdens. This study aimed to analyze historical trends in the burden of refractive disorders from 1990 to 2021 and to project future trends to 2050, focusing on global, socio-demographic, and key Asian regional levels.
methodsData on the prevalence and YLDs of refractive disorders were obtained from the Global Burden of Disease Study 2021. We analyzed age-standardized rates (ASR) globally, across five Socio-Demographic Index (SDI) quintiles, and for five Asian regions. Temporal trends were evaluated using Joinpoint regression to calculate the average annual percent change (AAPC). Future burden until 2050 was projected using a Bayesian Age-Period-Cohort (BAPC) model.
resultsFrom 1990 to 2021, the global age-standardized prevalence rate (ASPR) of refractive disorders decreased by 6.5%. The most significant declines occurred in low-SDI (11.8%) and low-middle-SDI (20.0%) regions. Among the selected Asian regions, Taiwan (10.1%) and China (6.4%) demonstrated the largest reductions. The burden was disproportionately high in older populations, with prevalence peaking in the 80–84 age group. Projections indicate a future shift in disease burden, with the ASPR in Japan and Taiwan forecasted to surpass that of China within the next decade.
conclusionWhile significant progress has been made in reducing the burden of refractive disorders, particularly in lower-SDI regions, the burden is increasingly concentrating in the aging populations of higher-SDI countries. These findings underscore the urgent need for targeted public health strategies and enhanced eye care services to address the challenges posed by these demographic shifts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.